Hasten Biopharmaceutic has acquired the commercial rights for Rocephin in China from Roche, including marketing authorization and certain intellectual property. Rocephin is a long-acting, broad-spectrum cephalosporin antibiotic with strong brand value. Hasten aims to become a leading innovative medical and healthcare enterprise in China and the acquisition delivers commercial synergy with the company’s current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments. The company is an investment of CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.
Hasten Biopharmaceutic Co., Ltd (China) (“Hasten”) today announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Following the closing of the transaction earlier this year, there will be a transition period between Hasten and Roche.
Under the agreement, Hasten acquired Roche’s China mainland rights for Rocephin®, including the product’s marketing authorization and certain intellectual property, including trademarks. As a critical care product, Rocephin® is a broad-spectrum antibiotic with strong brand value.
“Hasten is committed to building a leading innovative medical and healthcare enterprise in China. The acquisition of Rocephin® delivers strong commercial synergy with Hasten’s current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients,” Summer Xia, CEO of Hasten Biopharma, said.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Hasten is an investment of CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.
Source: BioSpace